PedAM
Pediatric Disease Annotations & Medicines
| Disease | sickle cell anemia |
| Phenotype | C0282193|iron overload |
| Sentences | 16 |
| PubMedID- 25711464 | Objective: to assess the prevalence of iron overload in adults with sickle cell disease (scd) not on a chronic transfusion protocol. |
| PubMedID- 21452907 | Pharmacoeconomic considerations in treating iron overload in patients with beta-thalassaemia, sickle cell disease and myelodysplastic syndromes in the us: a literature review. |
| PubMedID- 20687088 | Deferasirox for managing transfusional iron overload in people with sickle cell disease. |
| PubMedID- 25117103 | We assessed the frequency of the g71d mutation of the hamp gene and the h63d mutation of the hfe gene and the correlation between these mutations as well as the correlation between them and the iron overload in sickle cell disease (scd) patients. |
| PubMedID- 23580874 | This case-control study of only 30 patients demonstrates a clear difference between sickle cell anemia patients with and without iron overload by evidence of a distinct pathophysiology response of the immune system and the oxidative stress to iron overload. |
| PubMedID- 23018567 | Treatment of iron overload among women with sickle cell anemia of childbearing potential is important to avoid possible cdp in newborns. |
| PubMedID- 24319218 | Consequences and management of iron overload in sickle cell disease. |
| PubMedID- 24893174 | Deferasirox for managing transfusional iron overload in people with sickle cell disease. |
| PubMedID- 22760067 | Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients. |
| PubMedID- 20490352 | iron overload in sickle cell disease. |
| PubMedID- 22120913 | Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. |
| PubMedID- 23946212 | We report a prospective, randomized, phase ii study of deferasirox and deferoxamine (dfo) in sickle cell disease patients with transfusional iron overload, with all patients continuing on deferasirox after 24 weeks, for up to 2 years. |
| PubMedID- 20862206 | [8] provides an overview of transfusional iron overload patients with sickle cell disease, highlighting how to prevent iron overload in this disorder. |
| PubMedID- 21681718 | [iron overload in sickle cell anemia : a study of 94 patients]. |
| PubMedID- 22332939 | Serum ferritin and total units transfused for assessing iron overload in adults with sickle cell disease. |
| PubMedID- 21786315 | Chronic simple hypertransfusion (every 3 to 4 weeks) effectively prevents secondary stroke in children with sickle cell anemia but leads to iron overload despite chelation therapy. |
Page: 1